Back to search

Athens University Economics and Business (AUEB)

Adaptive designs in phase II clinical trials

Abstract

dc:description

Clinical trials play a very important role in the development process of new therapies. Recently there has been a rapid increase in the research and creation of new modern molecular agents, which makes necessary the development of more flexible and adaptive designs for the implementation of clinical trials. The objective of adaptive designs is to ensure direct and dynamic control of the effectiveness and the safety of a new treatment by allowing the adjustment of the elements of the study (i.e. sample size), during the study, in such a way that we will not sacrifice elements which arc associated with the credibility of the study (i.e statistical power) and also issues which concern ethical characteristics of the clinical trials. Under this light, the objective of this thesis is the investigation and the development of new flexible and adaptive clinical trial designs. Even though in the last years there is a huge progress in the comprehension of the pathophysiology for a great number of diseases and in the same a large number of new promising therapies have been developed, the 85% of these therapies fail at the early phases of clinical trials (Arrowsmith, 2011). One of the most important factors that could lead to an unsuccessful phase III clinical trial, is an inappropriate phase II study that provides inaccurate information about whether the therapy should proceed in a further phase III study or not (Gan et al., 2012). This is the reason why we have chosen to focus on the development of new adaptive designs for phase II clinical trials. Initially, we developed a new two-stage sample size re-estimation process, for phase II clinical trials, which enables as to adjust the required sample size based on the information given in the first stage and at the same time to maintain type I and II errors stable. While afterwards we addressed the issue that very often investigators face at the primary phases of clinical trials, which is the ambiguity in whether we have made the right choice of the targeted response level pA, which represents the level of response we believe the new therapy will have. For this reason we developed a new two-stage phase II adaptive design which allows as to adjust the response level target pA during the study, based on the data of the first stage. Based on the definition of the classical hypothesis of phase II clinical trials (H₀ : p ≤ p₀ vs HA : p ≥ pA), where p₀ is the response rate of the classical treatment and pa the target response level of the new therapy) we presented the misinterpretation problem that arises by the fact that the rejection of the null hypothesis (H₀ : p ≤ p₀) is not equivalent to the acceptance of the alternative hypothesis (HA : p ≥ pA) and vice versa which causes great confusion between statisticians and clinical investigators. In order to overcome this problem we developed a new phase II design in which we test two hypotheses sequentially (H₀₁: p ≤ p₀ vs HA₁ : p ≥ p0 and H₀₂ : p ≥ pA vs HA₂ : p < pA). The second null hypothesis (H₀₂) is tested only in the case that the first null hypothesis (H₀₁) is rejected and this fact makes the design more flexible. Finally due to the development, in the last years, of new cytostatic therapies which delay the progression of the disease without necessarily leading to its reduction or elimination we expanded the proposed design in the case that we use time-to-event as the endpoint for the evaluation of a phase II clinical trial.

Degree

thesis:*
Grantor dc:publisher
Athens University Economics and Business (AUEB)
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Poulopoulou, Stavroula
  • Πουλοπούλου, Σταυρούλα

Subjects

dc:subject × 22

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/30030

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Poulopoulou, Stavroula; Πουλοπούλου, Σταυρούλα. Adaptive designs in phase II clinical trials. Athens University Economics and Business (AUEB), 2013. http://hdl.handle.net/10442/hedi/30030